Paul Knoebl

Professor

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (18)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Wolfgang R. Sperr

AUSTRIA

View details

Johanna A. Kremer Hovinga

SWITZERLAND

View details

Katerina Pavenski

Head Division Transfusion Medicine

St. Michael's Hospital

CANADA

View details

Evelyn Seelow

Charité - Universitätsmedizin Berlin

GERMANY

View details

Ulf Schönermarck

GERMANY

View details

Christian Pfrepper

GERMANY

View details

Kathrin Eller

Assoc. Prof.

Medical University of Graz

AUSTRIA

View details

Spero R. Cataland

Ohio State University

UNITED STATES

View details

Adrian Schreiber

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Paul Knoebl

Research Interests

Explore related searches

Contact this professor

Articles (18)

Development of a rapid and fully automated factor VIII inhibitor assay, insensitive to emicizumab, and a lowest level of quantification of 0.2 BU/mL

Management of Immune Thrombotic Thrombocytopenic Purpura without Therapeutic Plasma Exchange

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura.

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study

N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.

Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study

Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study

100 Years of Thrombotic Thrombocytopenic Purpura: A Story of Death and Life

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.

Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study

Management of acquired hemophilia A in severe Covid-19: Hemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis.

Safer steps on a narrow path

Hereditary thrombotic thrombocytopenic purpura and COVID‐19: Impacts of vaccination and infection inrare disease

Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT)

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Emicizumab for the treatment of acquired hemophilia A

Collaborators (9)

Wolfgang R. Sperr

Johanna A. Kremer Hovinga

Katerina Pavenski

Evelyn Seelow

Ulf Schönermarck

Christian Pfrepper

Kathrin Eller

Spero R. Cataland

Adrian Schreiber

Make your next move.